Assessing the survival of exogenous plant microRNA in mice

Liang, Guozheng; Zhu, Ye; Sun, Bo; Shao, Youhua; Jing, Aihua; Wang, Junhua; Zhang, Xiao

doi:10.1002/fsn3.113

Cited by 126 publications

(118 citation statements)

References 32 publications

Supporting

Mentioning

113

Contrasting

Unclassified

Order By: Relevance

“…Expression of immune-modulatory miRNAs, especially miR-146a, has been determined in different diabetic complications, [48][49][50][51][52] including DN. 49,[53][54][55] While some studies have shown lower miR-146a expression during DN, 49 others have shown higher expression.…”

Section: Discussionmentioning

confidence: 99%

“…It is noteworthy that the expression of miR-146a is very sensitive to levels of proinflammatory mediators 56 and may follow a temporal or circadian pattern 51 and that, depending on the inflammation levels and tissues tested, miR-146a expression may show significant variations. Of note, the extent of miR-146a induction at 16 weeks after diabetes was much lower than at 7 weeks, suggesting a progressive decline of this "protective" miRNA during the development of DN.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Anti-Inflammatory Role of MicroRNA-146a in the Pathogenesis of Diabetic Nephropathy

Bhatt

Lanting

Jia

et al. 2015

JASN

159

130

View full text Add to dashboard Cite

Inflammation has a critical role in the pathogenesis of diabetic complications, including diabetic nephropathy (DN). MicroRNAs have recently emerged as important regulators of DN. However, the role of microRNAs in the regulation of inflammation during DN is poorly understood. Here, we examined the in vivo role of microRNA-146a (miR-146a), a known anti-inflammatory microRNA, in the pathogenesis of DN. In a model of streptozotocin-induced diabetes, miR-146a 2/2 mice showed significantly exacerbated proteinuria, renal macrophage infiltration, glomerular hypertrophy, and fibrosis relative to the respective levels in control wild-type mice. Diabetes-induced upregulation of proinflammatory and profibrotic genes was significantly greater in the kidneys of miR-146a 2/2 than in the kidneys of wild-type mice. Notably, miR146a expression increased in both peritoneal and intrarenal macrophages in diabetic wild-type mice. Mechanistically, miR-146a deficiency during diabetes led to increased expression of M1 activation markers and suppression of M2 markers in macrophages. Concomitant with increased expression of proinflammatory cytokines, such as IL-1b and IL-18, markers of inflammasome activation also increased in the macrophages of diabetic miR-146a 2/2 mice. These studies suggest that in early DN, miR-146a upregulation exerts a protective effect by downregulating target inflammation-related genes, resulting in suppression of proinflammatory and inflammasome gene activation. Loss of this protective mechanism in miR-146a 2/2 mice leads to accelerated DN. Taken together, these results identify miR-146a as a novel anti-inflammatory noncoding RNA modulator of DN. 27: 227727: -228827: , 201627: . doi: 10.1681 Diabetic nephropathy (DN) is the leading cause of CKD and ESRD. 1-6 Development and progression of DN involve a complex interplay among metabolic, hemodynamic, growth, and inflammatory factors. 1,3,[7][8][9][10][11][12][13] The progressive decline in renal function during DN is a result of a multitude of pathologic changes in the kidneys, including glomerular and tubular hypertrophy, macrophage infiltration, extracellular matrix (ECM) accumulation in multiple renal cells, mesangial expansion, endothelial dysfunction, and podocyte injury. 1,3,[7][8][9][10][11][12][14][15][16] These pathologic changes clinically manifest as proteinuria and a steady deterioration in GFR. 3,4,16 Identification of molecular pathways that contribute to the pathophysiology of DN is imperative for the development of new therapeutic strategies. J Am Soc NephrolConversely, identification of factors that exert adaptive and protective roles in the early stages of DN can be exploited to prevent progression to ESRD.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Anti-Inflammatory Role of MicroRNA-146a in the Pathogenesis of Diabetic Nephropathy

Bhatt

Lanting

Jia

et al. 2015

JASN

159

130

View full text Add to dashboard Cite

show abstract

“…However, it has been argued that the inability to detect the uptake of plant miRNAs was due to only looking at a few selected miRNAs rather than using sequencing to screen for all plant miRNAs. Furthermore, the cross-kingdom presence and potential function of plant miRNAs in mammals are supported by independent studies from only two different labs in the past three years, highlighting the need for further verification [22,[34][35][36].…”

Section: Introductionmentioning

confidence: 99%

Cross-kingdom inhibition of breast cancer growth by plant miR159

Fong²,

et al. 2016

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are critical regulators of gene expression, and exert extensive impacts on development, physiology, and disease of eukaryotes. A high degree of parallelism is found in the molecular basis of miRNA biogenesis and action in plants and animals. Recent studies interestingly suggest a potential cross-kingdom action of plant-derived miRNAs, through dietary intake, in regulating mammalian gene expression. Although the source and scope of plant miRNAs detected in mammalian specimens remain controversial, these initial studies inspired us to determine whether plant miRNAs can be detected in Western human sera and whether these plant miRNAs are able to influence gene expression and cellular processes related to human diseases such as cancer. Here we found that Western donor sera contained the plant miRNA miR159, whose abundance in the serum was inversely correlated with breast cancer incidence and progression in patients. In human sera, miR159 was predominantly detected in the extracellular vesicles, and was resistant to sodium periodate oxidation suggesting the plant-originated 2'-O-methylation on the 3′ terminal ribose. In breast cancer cells but not non-cancerous mammary epithelial cells, a synthetic mimic of miR159 was capable of inhibiting proliferation by targeting TCF7 that encodes a Wnt signaling transcription factor, leading to a decrease in MYC protein levels. Oral administration of miR159 mimic significantly suppressed the growth of xenograft breast tumors in mice. These results demonstrate for the first time that a plant miRNA can inhibit cancer growth in mammals.

show abstract

“…MiRNA-containing foods are found in animals and plant resources [68,69] [34,72]. First, some of the plant miRNAs in human serum are genuine plant miRNAs.…”

Section: Plant Mirnasmentioning

confidence: 99%